Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Stock Report

| More

Lupin Receives Tentative FDA Approvals for Generic Nuvigil Tablets and Generic Oracea Capsules

Posted On: 2013-08-13 03:17:43

MSD, one of the world's leading players in 23-valent Pneumococcal Polysaccharide Vaccines category and Lupin Limited have formed an India-specific strategic partnership. Within the scope of partnership, Lupin will have a non-exclusive license to market, promote and distribute 23-valent Pneumococcal Polysaccharide Vaccine under a different brand name in India.

Pneumococcal disease is an infection caused by bacteria named Streptococcus pneumoniae and it results in variety of invasive and non-invasive pneumococcal diseases with pneumonia being the most common presentation in adults. Pneumococcal disease kills more patients worldwide than any other vaccine preventable diseases. Worldwide 1.6 million people die of pneumococcal disease every year which translates to 3 people dying every minute. Adults with co morbid conditions like chronic lung disease (COPD etc.), diabetes, chronic heart diseases, chronic liver diseases, immune compromised diseases as well as adults more than 65 years of age are at increased risk for pneumococcal diseases than healthy adults.

A recent study from India showed that the case fatality rate due to invasive pneumococcal disease observed in elderly is 26.4% which is much higher than that in children and highlights the need for preventive interventions in adults1

Identifying this significant risk, this partnership is built on a patient centric model, which will help improve vaccination rate for pneumococcal disease, in particular to high risk population group to help reduce incidence and mortality in adults.

Pneumococcal polysaccharide vaccine (PPV)

- Pneumococcal polysaccharide vaccine (PPV) addresses the need of prevention of pneumococcal disease in India with its proven efficacy and broader coverage.

- PPV23 provides broader coverage and has proven efficacy for prevention of pneumococcal diseases which help addresses the need of prevention of pneumococcal disease in India

- Based on the clinical experience since last 3 decades, PPV23 has good safety profile

- Recent India focused study showed that more than 80% of invasive serotype groups of Streptococcus pneumoniae causing disease in the elderly in India are included in the formulation of PPV 23 which makes this vaccine relevant from India perspective

- PPV23 is recommended worldwide for prevention of pneumococcal diseases in adults by leading medical societies like Advisory committee on Immunization Practices, American Diabetes Association, American Thoracic society, Geriatric society of India etc.

Shares of Lupin Ltd was last trading in BSE at Rs.839.60, up by Rs.20.40 or 2.49%. The stock hit an intraday high of Rs.847.55 and low of Rs.817.60.

The total traded quantity was 0.73 lakhs compared to 2 week average of 1.45 lakhs.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

The Phoenix Mills Limited's Long-Term Issuer Rating upgraded by India Ratings from 'IND A' to 'IND A+'
NASSCOM confers L&T Technology Services Limited with prestigious Digital Skills Award for 2017
Trigyn Technologies Inc announces extension in contract by UN, OICT
Shankara Building Products Limited opens its 117th Store
A2Z Infra Engineering Limited approves One Time Settlement of debts
Satin Creditcare Network Ltd to consider issue of NCDs upto Rs. 65 crores
Paul Merchants Ltd approves slump sale of MTSS Business
Repco Home Finance Ltd approves appointment of Director
Virtual Global Education Ltd announces new Company Secretary
Raunaq EPC International Ltd announces resignation of Chief Financial Officer
KNR Constructions Ltd JV bags order worth Rs. 884.47 crores
Ravi Uppal ceased to be Director of Jindal Steel & Power Limited
ICRA revises ratings of KRBL Ltd
Zydus receives final approval from the USFDA for Itraconazole Capsules 100 mg
Vivimed Labs FDF facility in Jeedimetla obtains Ukraine GMP approval
TCI Express Ltd calls for Board Meeting On November 1, 2017
Ruchira Papers Ltd proposes setting up of greenfield plant
ITI Ltd declared as L1 in ASCON Phase IV Project
Claris Lifesciences Ltd completes sale of its stake in JV to Otsuka
GHCL's Credit Rating Upgraded by CARE Ratings Ltd
Petron Engineering Construction Ltd calls for Board Meeting on Sep 28, 2017
Alpine Housing Development Corporation Limited announces resignation of Independent Director
Dr. Reddy's Laboratories Ltd announces completion of audit by USFDA
Orchid Pharma Ltd receives EIR from USFDA
CARE upgrades SE Forge rating to Investment Grade BBB+
Shree Global Tradefin Ltd announces resignation of Company Secretary
Intellect Risk Analyst Bags the Prestigious SMA Innovation in Action Award
Bajaj Holdings & Investment Limited to announce Q2 results on Oct 17, 2017
Bajaj Auto to consider Q2 results on Oct 17, 2017
L&T Technology Services Collaborating with Wind River for Intelligent Systems
Maharashtra Scooters Ltd to approve Q2 results on Oct 14, 2017
Tata Communications' new Americas chief to drive growth for U.S. enterprises across borders
Allahabad Bank Ltd approves merger of AllBank Finance Ltd
Entertainment Network India Limited commences broadcast of radio station from Kozhikode
Northlink Fiscal and Capital Services Ltd calls for Board Meeting On 25.09.2017
Den Networks Ltd receives assent from NCLT for demerger of broadband undertaking
Shelter Infra Projects Limited receives OTS proposal from SBI
Trident Limited receives 'Confederation of Indian Textile Industry (CITI) Award for Excellence'
Gujarat Natural Resources Limited announces resignation of independent director
Insilco to shut plant from Sep 21, 2017 to Oct 5, 2017
ICRA A1+ rating assigned to HSIL Limited
City Union Bank Ltd Opens of 555th branch at Muthupet
NBCC India Ltd receives LOI for Rs. 3200 crores project
Unichem Laboratories Ltd receives ANDA approval from USFDA for Irbesartan and Hydrochlorothiazide Tablets USP
Mahindra Farm Equipment strengthens its position in Turkey
G N A Axles Ltd starts commercial production at new line
KPIT Technologies Limited announces resignation of Mr. Sanjay Kukreja
Gujarat Industries Power Company in race for 75 MW solar power project
Europe's Premium Global Brewery brand chooses Ramco HCM for its Malaysia operations
Mr M V Murugappan Passes Away


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017